Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This pilot study is designed to determine feasibility and safety of treatment with dasatinib
administered orally once daily for 4 weeks duration prior to radical cystectomy for
urothelial carcinoma of the bladder.